PALBOCICLIB SLOWS TUMOUR GROWTH IN BREAST CANCER

摘要

Adding the ODK4/6 inhibitor palbociclib to hormone therapy can slow or stop tumour growth in women with early breast cancer,a study in the Journal of Clinical Oncology has shown(6 December 2018).The 14-week trial involved 307 postmenopausal women with oestrogen receptor-positive primary breast cancer with a tumour of at least 2om.Patients were randomly assigned to one of four groups: letrozole alone for 14 weeks,letrozole and palbooiclib for 14 weeks,or letrozole or palbociclib alone for two weeks followed by 12 weeks of letrozole and palbociclib.